CN1674909A - 甲酰胺类在治疗耳鸣中的用途 - Google Patents

甲酰胺类在治疗耳鸣中的用途 Download PDF

Info

Publication number
CN1674909A
CN1674909A CNA03818835XA CN03818835A CN1674909A CN 1674909 A CN1674909 A CN 1674909A CN A03818835X A CNA03818835X A CN A03818835XA CN 03818835 A CN03818835 A CN 03818835A CN 1674909 A CN1674909 A CN 1674909A
Authority
CN
China
Prior art keywords
formula
compound
tinnitus
expression
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA03818835XA
Other languages
English (en)
Chinese (zh)
Inventor
M·施穆茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218243A external-priority patent/GB0218243D0/en
Priority claimed from GB0218244A external-priority patent/GB0218244D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1674909A publication Critical patent/CN1674909A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA03818835XA 2002-08-06 2003-08-05 甲酰胺类在治疗耳鸣中的用途 Pending CN1674909A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0218243A GB0218243D0 (en) 2002-08-06 2002-08-06 Organic compounds
GB0218244A GB0218244D0 (en) 2002-08-06 2002-08-06 Organic compounds
GB0218243.4 2002-08-06
GB0218244.2 2002-08-06

Publications (1)

Publication Number Publication Date
CN1674909A true CN1674909A (zh) 2005-09-28

Family

ID=31716915

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA03818835XA Pending CN1674909A (zh) 2002-08-06 2003-08-05 甲酰胺类在治疗耳鸣中的用途

Country Status (8)

Country Link
US (1) US7465723B2 (cg-RX-API-DMAC10.html)
EP (1) EP1528927A1 (cg-RX-API-DMAC10.html)
JP (1) JP2005538126A (cg-RX-API-DMAC10.html)
CN (1) CN1674909A (cg-RX-API-DMAC10.html)
AU (1) AU2003266965A1 (cg-RX-API-DMAC10.html)
BR (1) BR0313230A (cg-RX-API-DMAC10.html)
CA (1) CA2494660A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004014391A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103980270A (zh) * 2014-05-19 2014-08-13 埃斯特维华义制药有限公司 一种（r）-3-奎宁醇的制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303615D0 (en) * 2003-02-17 2003-03-19 Novartis Ag Use of organic compounds
PE20051156A1 (es) * 2004-03-22 2006-02-13 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
EP2380573B1 (en) * 2005-05-06 2015-02-25 Bial-Portela & CA, S.A. Eslicarbazepine acetate and methods of use
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US9410427B2 (en) * 2012-06-05 2016-08-09 United Technologies Corporation Compressor power and torque transmitting hub
US8920855B1 (en) 2012-10-30 2014-12-30 Setem Hemth, Inc Methods of topically treating tinnitus and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472714A (en) 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IL125244A (en) 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103980270A (zh) * 2014-05-19 2014-08-13 埃斯特维华义制药有限公司 一种（r）-3-奎宁醇的制备方法

Also Published As

Publication number Publication date
JP2005538126A (ja) 2005-12-15
WO2004014391A1 (en) 2004-02-19
BR0313230A (pt) 2005-07-12
US20060106009A1 (en) 2006-05-18
WO2004014391B1 (en) 2004-04-15
CA2494660A1 (en) 2004-02-19
EP1528927A1 (en) 2005-05-11
US7465723B2 (en) 2008-12-16
AU2003266965A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
TWI298020B (en) Gabapentin analogues for sleep disorders
CN112930175A (zh) 治疗癫痫的方法
US9096494B2 (en) Arachidonic acid analogs and methods for analgesic treatment using same
US20100120746A1 (en) Use of r-10-hydroxy-10,11-dihydro-carbamazepine in neuropathic pain
US20100016440A1 (en) Alpha-aminoamide derivatives useful as anti-inflammatory agents
US20100063029A1 (en) Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
ES2347581T3 (es) Uso de (r)-(halobenciloxi)bencilamino-propanamidas como moduladores selectivos del canal de sodio y/o calcio.
EA003097B1 (ru) Замещенные 2-бензиламино-2-фенилацетамидные соединения
US7465723B2 (en) Use of carboxamides for the treatment of tinnitus
EP1745786B1 (fr) Composés neuroprotecteurs et compositions pharmaceutiques les comprenant
US6011070A (en) Slow-onset, long-lasting dopamine reuptake blockers
JP5749176B2 (ja) トリプル再取込み阻害剤及びそれらの使用方法
CN1747735A (zh) S－10－羟基－10,11－二氢－卡马西平在治疗焦虑和双相情感障碍中的用途
WO2023076997A1 (en) Modified forms of ambroxol for therapeutic use
RU2008112310A (ru) Соединение тиоморфолина и способ его получения
FR2852246A1 (fr) Utilisation de l&#39;oxime de cholest-4-en-3-one dans le traitement des affections du motoneurone
TW200800157A (en) Alpha-2-delta ligands for non-restorative sleep
AU2007251901A1 (en) Use of S-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication